Introduction
If you have looked at the clinical research section on the Nova Digestive website and wanted to understand what it actually means, this article is for you.
The peppermint oil and caraway oil combination has one of the most well-documented evidence bases of any botanical compound applied to functional digestive complaints. It has been studied in randomised controlled trials, subjected to multiple independent meta-analyses, and its mechanism of action is documented in pharmacological literature. This is not anecdotal. This is published research.
This article walks through what five clinical trials actually showed, what the numbers mean in plain language, and what the evidence does and does not tell us.
What Is Functional Dyspepsia?
Before the research makes sense, it helps to understand what functional dyspepsia means clinically.
Functional dyspepsia is a medical term for chronic upper abdominal discomfort, including post-meal pressure, bloating, early fullness, trapped gas, and epigastric pain, in patients where standard diagnostic tests find no structural abnormality. The stomach, intestines and oesophagus appear normal. The tests come back clean. And yet the symptoms persist, often after every meal, often for years.
It is estimated to affect between 10% and 30% of the general population, making it one of the most prevalent functional gastrointestinal disorders in the world. It is also, notably, one of the conditions for which conventional pharmaceutical medicine has the fewest effective tools, because it is a functional pattern, not a structural disease.
The peppermint-caraway combination has been studied specifically for this patient population.
The Mechanism: Why These Two Botanicals Were Combined
Peppermint oil (Mentha piperita) and caraway oil (Carum carvi) were not selected arbitrarily. Each has a distinct and documented mechanism of action on the gastrointestinal tract, and they are complementary.
Peppermint oil contains L-menthol as its primary active compound. L-menthol has established antispasmodic effects on the smooth muscle of the gastrointestinal tract. It activates cold-sensitive receptors (TRPM8 channels) in the gut wall, which inhibit smooth muscle contraction. The practical effect is a relaxation of intestinal smooth muscle that reduces spasm, lowers intraluminal pressure, and allows gas to move more freely through the digestive tract rather than accumulating into the pressure and bloating that follows meals.
Caraway oil (Carum carvi) contains carvone and limonene as its primary active compounds. Carvone has documented carminative properties, relaxing the smooth muscle of the stomach and upper intestine, supporting gastric emptying and the natural movement of gas through the digestive system. It has also demonstrated mild antispasmodic activity in preclinical research.
Together, peppermint oil and caraway oil work on the same system, gastrointestinal smooth muscle tone and motility, from complementary angles. Peppermint primarily reduces spasm and pressure. Caraway supports gastric motility and gas clearance. The fixed combination has been consistently studied as a unit because the combined effect is greater than either component individually.
Trial 1: May et al. 1996 — The First Major RCT
Reference: May B, Kuntz H-D, Kieser M, et al. Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia. Arzneimittelforschung. 1996;46:1149-53. PMID: 9006790.
The first randomised controlled trial on the fixed peppermint-caraway combination was published in 1996 by May and colleagues. This was a double-blind, placebo-controlled study in patients with non-ulcer dyspepsia, the historical term for what is now classified as functional dyspepsia.
The study evaluated the efficacy of the fixed combination against placebo over a defined treatment period. Patients receiving the active combination showed statistically significant improvements in pain intensity compared to placebo. The results established the initial evidence base for the combination and formed the foundation for subsequent trials.
This was the first controlled study to document that the peppermint-caraway combination produced measurable improvements in functional digestive symptoms beyond placebo effect, a critical methodological threshold.
Trial 2: Madisch et al. 1999 — Equivalence With a Pharmaceutical Reference
Reference: Madisch A, Heydenreich CJ, Wieland V, Hufnagel R, Hotz J. Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled double-blind equivalence study. Arzneimittelforschung. 1999;49(11):925-32. PMID: 10604046.
The 1999 Madisch et al. study is the most frequently cited individual trial on the peppermint-caraway combination. It addressed a specific and clinically meaningful question: how does the botanical combination compare to an established pharmaceutical agent?
The comparison drug was cisapride, a prokinetic agent, a pharmaceutical that accelerates gastric emptying and intestinal transit, that was, at the time, a standard treatment for functional dyspepsia in many countries. Cisapride was subsequently withdrawn from several markets due to cardiac side effects, which is relevant context.
Study Design
Multicenter, reference-controlled, double-blind, randomised equivalence study. Four weeks of treatment. 120 outpatients with functional dyspepsia. Efficacy evaluated in 118 patients. 60 patients received the peppermint-caraway combination (90mg peppermint oil + 50mg caraway oil per day in enteric-coated capsules). 58 patients received cisapride (3 × 10mg per day).
Primary Outcome
Mean reduction in pain score on a Visual Analog Scale (VAS) over four weeks.
Results
The mean reduction in pain score was 4.62 points in the peppermint-caraway group versus 4.60 points in the cisapride group. The confidence interval for the difference fell within the pre-specified equivalence bounds, confirming therapeutic equivalence between the botanical combination and the pharmaceutical agent.
Secondary outcomes, the Dyspeptic Discomfort Score, physician prognosis assessment, and Clinical Global Impressions (CGI) scales, showed comparable results between the two groups. Results were consistent regardless of Helicobacter pylori status.
The peppermint-caraway combination performed equivalently to a pharmaceutical prokinetic agent across a four-week randomised controlled trial. A botanical combination matched the performance of the standard drug, without the cardiac side effects that eventually led to cisapride's withdrawal.
The 2019 Meta-Analysis: Five Trials, 578 Patients
Reference: Li J, Lv L, Zhang J, et al. A Combination of Peppermint Oil and Caraway Oil for the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. 2019;2019:7654947. PMC6885176.
The 2019 meta-analysis by Li and colleagues is the most statistically comprehensive evaluation of the peppermint-caraway evidence base to date. It pooled data from five randomised controlled trials including 578 participants.
Search Methodology
The authors searched CENTRAL, PubMed, EMBASE (Ovid), Web of Science, Google Scholar, China National Knowledge Infrastructure database, Wanfang, and VIP databases for all randomised clinical trials up to June 2019. From 382 identified citations, five RCTs met the inclusion criteria.
Primary Outcome — Global Improvement of Functional Dyspepsia Symptoms
Four of the five eligible studies, covering 350 participants, reported outcomes using the Clinical Global Impression (CGI) Item 2 scale, a validated investigator-rated measure of overall symptom improvement.
Results: 56.2% of patients receiving the peppermint-caraway combination reported much or very much improved symptoms. 25.6% of patients receiving placebo reported the same level of improvement. The risk ratio was 0.59 (95% CI: 0.49 to 0.71), with a p-value of less than 0.00001, a high level of statistical significance.
The Number Needed to Treat (NNT) was 3.
The NNT is one of the most clinically useful statistics in medicine. It answers the question: for how many patients do you need to treat with this intervention for one additional patient to benefit, compared to placebo? An NNT of 3 means that for every three patients treated with the peppermint-caraway combination, one additional patient experienced meaningful global improvement who would not have improved on placebo.
To put this in context: an NNT of 3 is considered a clinically significant result. For comparison, common pharmaceutical interventions for various conditions often have NNTs ranging from 5 to 20 or higher. An NNT of 3 places the peppermint-caraway combination among the more effective interventions studied for functional digestive complaints.
Secondary Outcome — Epigastric Pain Improvement
All five studies reported epigastric pain outcomes. The risk ratio for pain improvement was 1.61 (95% CI: 1.28 to 2.03, p < 0.0001), with an I² of 0%, meaning no heterogeneity was detected between studies. The NNT for epigastric pain improvement was also 3.
Safety Profile
There were no statistically significant differences in total adverse events between the peppermint-caraway group and placebo. The Number Needed to Harm (NNH) was 40, indicating a favourable safety profile relative to efficacy.
Conclusion of the Meta-Analysis
The authors concluded that the peppermint-caraway combination is an effective and safe short-term treatment for functional dyspepsia, based on five randomised controlled trials covering 578 participants.
The 2023 Systematic Review: Broader Gastrointestinal Complaints
Reference: Madisch A et al. Menthacarin, a Proprietary Peppermint Oil and Caraway Oil Combination, Improves Multiple Complaints in Patients with Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis. Digestive Diseases. 2023;41(3):522. Karger Publishers.
The 2023 systematic review and meta-analysis, published in the journal Digestive Diseases by Karger Publishers, extended the evidence base beyond functional dyspepsia to a broader range of functional gastrointestinal disorders including irritable bowel syndrome.
The review examined a proprietary standardised combination of peppermint oil and caraway oil (Menthacarin) across multiple randomised placebo-controlled trials. The meta-analysis used standardised mean differences and random effects modelling to evaluate change in pain intensity after four weeks of treatment.
The results confirmed statistically significant reductions in pain intensity compared to placebo across multiple functional gastrointestinal diagnoses. The authors concluded that the peppermint-caraway combination demonstrated consistent clinical benefit in disorders of gut-brain interaction, a category that encompasses the functional patterns, including post-meal gas pressure, bloating and dyspeptic discomfort, that most patients dealing with chronic digestive complaints recognise.
What the Evidence Does and Does Not Show
What It Shows
The peppermint-caraway combination has been studied in randomised controlled trials, with results replicated across independent research groups. A meta-analysis of five RCTs covering 578 patients demonstrates statistically significant global symptom improvement with an NNT of 3. The combination has been shown equivalent to a pharmaceutical prokinetic agent in a reference-controlled trial. The safety profile is comparable to placebo.
What It Does Not Show
The individual trials were conducted with specific formulations and doses. The Madisch 1999 trial used 90mg peppermint oil and 50mg caraway oil per day in enteric-coated capsules. Results cannot be mechanically applied to every formulation, dose, or delivery format. Individual results vary.
The studies were conducted in patients with diagnosed functional dyspepsia. The evidence base applies most directly to this population. Individuals with structural gastrointestinal pathology, specific medical conditions, or those on prescription medication should consult a healthcare provider before using botanical supplements.
References
- May B, Kuntz H-D, Kieser M, et al. Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia. Arzneimittelforschung. 1996;46:1149-53. PMID: 9006790.
- Madisch A, Heydenreich CJ, Wieland V, Hufnagel R, Hotz J. Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled double-blind equivalence study. Arzneimittelforschung. 1999;49(11):925-32. PMID: 10604046. pubmed.ncbi.nlm.nih.gov/10604046
- Li J, Lv L, Zhang J, et al. A Combination of Peppermint Oil and Caraway Oil for the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. 2019;2019:7654947. PMC6885176. ncbi.nlm.nih.gov/pmc/articles/PMC6885176
- Madisch A, et al. Menthacarin, a Proprietary Peppermint Oil and Caraway Oil Combination, Improves Multiple Complaints in Patients with Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis. Digestive Diseases. 2023;41(3):522. karger.com/ddi/article/41/3/522
